Rhucin Articles
Pharming extends Ruconest deal with SOBI
16 August 2011
FDA turns down 'incomplete' Rhucin dossier
1 March 2011
Pharming licenses North American rights to HAE drug Rhucin to Santarus for upfront $15 million
14 September 2010
Pharming plans to file Rhucin BLA with US FDA by end 2010
31 August 2010
Showing 1-7 of 7 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
